Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Aminoglutethimide may speed up how quickly your body processes tamoxifen.
What might happen:
The amount of tamoxifen in your blood may not work as well. At the same time, taking both of these medicines together may increase your risk of side effects.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Let your doctor know if you develop a rash; easy bruising or bleeding; signs of an infection such as fever, chills, or persistent sore throat; or fatigue.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Nolvadex (tamoxifen citrate) US prescribing information. AstraZeneca Pharmaceuticals LP March, 2006.
2.Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 1990 Sep 15;50(18):5851-7.
3.Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 2003 Mar 15;21(6):984-90.
4.Rose C, Kamby C, Mouridsen HT, Andersson M, Bastholt L, Moller KA, Andersen J, Munkholm P, Dombernowsky P, Christensen IJ. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. Breast Cancer Res Treat 2000 May;61(2):103-10.
5.Alonso-Munoz MC, Ojeda-Gonzalez MB, Beltran-Fabregat M, Dorca-Ribugent J, Lopez-Lopez L, Borras-Balada J, Cardenal-Alemany F, Gomez-Batiste X, Fabregat-Mayol J, Viladiu-Quemada P. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 1988;45(5):350-3.
6.Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmonson JH, Rubin J, Chang MN, Creagan ET. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 1986 Jun;4(6):958-64.
7.Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Skovgaard-Poulsen H, Andersen AP, Loft H, Dombernowsky P, Andersen KW. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. Breast Cancer Res Treat 1986;7 Suppl:S45-50.
8.Smith IE, Harris AL, Stuart-Harris R, Ford HT, Gazet JC, White H, Harmer CL, Carr L, McKinna JA, Morgan M. Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer. Br Med J (Clin Res Ed) 1983 May 21;286(6378):1615-6.
9.Hisamatsu K, Nomura Y, Tashiro H. Aminoglutethimide and aminoglutethimide plus tamoxifen treatment for advanced breast cancer. Gan To Kagaku Ryoho 1992 Oct;19(12):2017-23.
10.Smith IE, Harris AL, Morgan M, Gazet JC, McKinna JA. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 1982 Aug;42(8 Suppl):3430s-3433s.
11.Dowsett M, Harris AL, Smith IE, Jeffcoate SL. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer. Br J Cancer 1984 Sep;50(3):357-61.